Aviance Capital Partners LLC Sells 1,000 Shares of Jazz Pharmaceuticals PLC $JAZZ

Aviance Capital Partners LLC lowered its stake in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 11.3% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 7,817 shares of the specialty pharmaceutical company’s stock after selling 1,000 shares during the period. Aviance Capital Partners LLC’s holdings in Jazz Pharmaceuticals were worth $830,000 at the end of the most recent reporting period.

Several other large investors have also added to or reduced their stakes in JAZZ. GAMMA Investing LLC boosted its holdings in Jazz Pharmaceuticals by 63.7% in the first quarter. GAMMA Investing LLC now owns 1,015 shares of the specialty pharmaceutical company’s stock valued at $126,000 after acquiring an additional 395 shares in the last quarter. Wealth Enhancement Advisory Services LLC boosted its holdings in shares of Jazz Pharmaceuticals by 5.7% during the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 4,334 shares of the specialty pharmaceutical company’s stock valued at $538,000 after buying an additional 232 shares in the last quarter. Principal Financial Group Inc. boosted its holdings in shares of Jazz Pharmaceuticals by 0.3% during the 1st quarter. Principal Financial Group Inc. now owns 139,041 shares of the specialty pharmaceutical company’s stock valued at $17,262,000 after buying an additional 378 shares in the last quarter. OneDigital Investment Advisors LLC boosted its holdings in shares of Jazz Pharmaceuticals by 10.6% during the 1st quarter. OneDigital Investment Advisors LLC now owns 3,932 shares of the specialty pharmaceutical company’s stock valued at $488,000 after buying an additional 377 shares in the last quarter. Finally, GF Fund Management CO. LTD. boosted its holdings in shares of Jazz Pharmaceuticals by 22.0% during the 1st quarter. GF Fund Management CO. LTD. now owns 1,548 shares of the specialty pharmaceutical company’s stock valued at $192,000 after buying an additional 279 shares in the last quarter. Institutional investors own 89.14% of the company’s stock.

Insiders Place Their Bets

In other Jazz Pharmaceuticals news, Director Bruce C. Cozadd sold 6,000 shares of the business’s stock in a transaction dated Tuesday, September 2nd. The stock was sold at an average price of $128.62, for a total value of $771,720.00. Following the completion of the transaction, the director owned 429,973 shares of the company’s stock, valued at approximately $55,303,127.26. The trade was a 1.38% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Over the last ninety days, insiders sold 11,500 shares of company stock valued at $1,525,280. 4.30% of the stock is currently owned by insiders.

Jazz Pharmaceuticals Price Performance

JAZZ opened at $137.64 on Friday. The stock has a 50-day moving average price of $132.19 and a 200-day moving average price of $118.24. The company has a debt-to-equity ratio of 1.17, a current ratio of 1.62 and a quick ratio of 1.37. The firm has a market cap of $8.35 billion, a PE ratio of -20.45, a P/E/G ratio of 8.49 and a beta of 0.28. Jazz Pharmaceuticals PLC has a 1 year low of $95.49 and a 1 year high of $148.06.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last posted its quarterly earnings results on Tuesday, August 5th. The specialty pharmaceutical company reported ($8.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($5.61) by ($2.64). The company had revenue of $1.05 billion during the quarter, compared to analysts’ expectations of $1.05 billion. Jazz Pharmaceuticals had a positive return on equity of 5.02% and a negative net margin of 9.91%.Jazz Pharmaceuticals’s revenue for the quarter was up 2.1% compared to the same quarter last year. During the same period in the prior year, the firm earned $5.30 EPS. Jazz Pharmaceuticals has set its FY 2025 guidance at 4.800-5.600 EPS. Sell-side analysts predict that Jazz Pharmaceuticals PLC will post 16.96 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts have recently commented on the stock. JPMorgan Chase & Co. dropped their target price on shares of Jazz Pharmaceuticals from $204.00 to $199.00 and set an “overweight” rating on the stock in a report on Monday, October 27th. Royal Bank Of Canada boosted their target price on shares of Jazz Pharmaceuticals from $145.00 to $151.00 and gave the company an “outperform” rating in a report on Thursday, August 28th. Deutsche Bank Aktiengesellschaft assumed coverage on shares of Jazz Pharmaceuticals in a report on Tuesday, July 15th. They set a “buy” rating and a $152.00 target price on the stock. Wells Fargo & Company set a $170.00 target price on shares of Jazz Pharmaceuticals in a report on Wednesday, October 22nd. Finally, The Goldman Sachs Group boosted their target price on shares of Jazz Pharmaceuticals from $162.00 to $185.00 and gave the company a “buy” rating in a report on Friday, August 29th. Fourteen analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $179.33.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.